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ABSTRACT 
 
Detection of biomarkers using DNA biosensors in a fluorescent platform to improve current 
one-step point-of-care methodologies 
by 
Hannah Marie Kallewaard-Lum 
 
Current methodologies for patient diagnosis require the use of skilled workers, 
expensive reagents, instrumentation, and most importantly, time. As these methodologies 
encourage inconsequential follow-up between patients and their doctors, new methods must 
be developed. These methods should follow the World Health Organization (WHO) 
ASSURED guidelines (Accessible to those in need, Sensitive to the clinical range of the 
target of interest, Specific to the target of interest with no false positives or negatives, User-
friendly, Rapid, under one hour for results, Equipment free, and Delivered to those in need) 
to create point of care technologies available for all. To this end, my studies focus on the 
development of convenient calibration methods for use with fluorescent, aptamer-based 
biosensors (aptamer beacons). Specifically, I describe here the creation, characterization, 
and application of a one-tube method for the calibration of aptamer beacons using sensors 
for the detection of DNA, silver ions, and thrombin as my test bed. 
A significant hurdle in the point of care testing of biomarkers in complex solutions is 
that there is sample variation, requiring large volumes of the target of interest and complex 
and cumbersome calibration. In response, I have created a simple, three-step, one-tube 
method for the calibration of aptamer beacons supporting the direct quantification of 
  vii 
specific target molecules within complex sample matrices. Specifically, I have shown that 
the sequential addition of two inexpensive and stable oligonucleotide-based reagents allows 
for the determination of the absolute minimum and maximum fluorescence produced by the 
sensor in each solution, providing the information to calibrate in the face of sample-to-
sample variations in a simple, single-tube format. Using these three measurements together 
with the pre-determined disassociation constant of the aptamer, I demonstrate the single-
tube calibrated quantification of multiple targets directly in complex samples.  
  viii 
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Chapter 1. Introduction 
1.1 Molecular Diagnostics  
The molecular markers associated with infectious diseases,1,2 oncology,3 
pharmacogenomics,4 genetic disease screening,5 antigen typing,6 and blood biomarkers7,8 
spurred the world of molecular diagnostics. This type of testing determines any changes 
from a normal sequence in a specific space of deoxyribonucleic acid (DNA) or ribonucleic 
acid (RNA) sequences,9 the concentration of some protein or small molecule biomarker, and 
the detection and quantification of specific pathogens.10  
Current molecular diagnostic testing technology requires multiple steps and 
transfers, but most importantly, it often takes days until the patient is diagnosed.11 Only after 
a patient enters the doctor’s office can the doctor decide to order a blood test since patients 
cannot order their own testing. The patient then must travel to a phlebotomist, sometimes in 
the same facility or possibly in another location. Once there, the process of drawing the 
patient’s blood is performed, which can be difficult for a person who is dehydrated, cold, 
undernourished, or simply has small veins. Upon collection, the blood sample, it is then 
labeled and transported to the central laboratory for testing.  
Central laboratories are specialized facilities that receive samples from local 
collection centers and perform a range of complex testing protocols. This testing requires 
skilled workers who have been educated in techniques and troubleshooting of expensive and 
specific equipment and reagents. A knowledgeable staff runs the equipment and interprets 
results. This “overhead” costs large sums of money, which is why modern molecular testing 
uses the central laboratory framework rather than using smaller testing sites located close to 
or at the point of care e.g. hospital, doctors offices, operating areas, etc. 
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An additional factor for the centralized facilities approach to molecular diagnostics is 
the complexity of current testing approaches. Once a sample arrives at the central laboratory, 
it queues for the many steps it must undergo to complete testing. Frequently samples are 
batch tested;12 meaning many samples destined for the same type of testing must be 
collected before the test is run. Although this saves the company money, it costs the patient 
precious time in obtaining a diagnosis. In addition, whole blood samples often cannot be 
used directly for the testing, but instead must be centrifuged to separate the sample into 
serum and red blood cells. Some tests require even more processing of the blood sample. 
Every test is then run in triplicate to validate results, and calibrations are verified for proper 
reporting. The results are then sent back to the doctor for reporting. The entire process takes 
anywhere between a few days to six months, painfully slow for patients whose health 
management depends on the results. 
The centralized facility approach to testing significantly harms healthcare for 
patients. This method cannot be completed within the average doctor visit of 10 minutes, 
thus requiring a follow-up visit between the doctor and patient. However, research shows 
deficient patient follow up if a second contact is required, especially in low-resource areas. 13 
Usually, it is crucial for the patient to receive counseling on the results and to determine the 
path of treatment.  
To combat these lengthy testing times and expensive testing, there is a push toward 
point-of-care technologies. The term point-of-care simply means that the test can be easily 
administered wherever the test is needed and gives results in a reasonable amount of time. 
The World Health Organization (WHO) has set guidelines for this type of testing with a 
mnemonic acronym, ASSURED.14 These guidelines dictate that tests should be: 
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Accessible to those in need 
Sensitive to the clinical range of the target of interest 
Specific to the target of interest, no false positives or negatives 
User-friendly 
Rapid, under one hour for results 
Equipment free 
Delivered to those in need 
Testing that remains within these guidelines solves many of the problems outlined above in 
regard to lengthy and expensive testing. Thus, these technologies can significantly improve 
outcomes and costs for patients by shortening time to diagnosis, and therefore treatment.  
Although some progress toward WHO-approved point of care devices has been 
achieved, much remains to be achieved to reach these goals fully. Excellent examples of 
current point-of-care testing are seen in urine dipsticks, glucose meters, and urine pregnancy 
tests. Most of these tests separate the target protein or analyte from a complex solution, 
amplify the target, and then detect the target all in one system. The urine pregnancy test is an 
example of a lateral flow test, where the target human chorionic gonadotropin (hCG)15 is 
separated from the urine in the initial absorbent material, and then the hCG is concentrated 
by binding to an antibody which is covalently bound to an optical reporter. Then this 
complex binds to another antibody for hCG in a pattern that can be read by the user. 
Distinctly, testing like the pregnancy and urine dipsticks are qualitative, providing only yes 
or no answers. While this works well for pregnancy, other types of testing require 
quantitative results to understand outcomes, such as the glucose measurements diabetics use 
to determine their need for insulin. Unfortunately, the technology behind glucose monitoring 
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cannot be applied to other targets. This is because the specific enzyme that detects glucose 
converts it into hydrogen peroxide, which is read electrochemically.16 Very few recognition 
enzymes are able to turn their targets into electrochemically active products for detection. 
Instead, progress requires technologies with a new approach that remains within the WHO 
guidelines.  
To better understand new approaches to point of care technologies, it is important to 
understand the gold standards used for current testing methods. These techniques involving 
microarrays, the polymerase chain reaction (PCR), and Enzyme-Linked Immunosorbent 
Assays (ELISA), are often modified from their existing platforms in an effort to create point 
of care methodologies. Scientists pushing technologies forward often pull from these 
established methods habitually, as they are well understood by the scientific community. 
 
1.1.1 Microarrays 
This type of testing, also called multiplexing, is used to simultaneously screen a wide 
range of binding events, allowing for large sets of data to be collected.17 As compared to 
other arrays, microarrays use small volumes in small spaces. Inspired by ELISAs that used 
196+ well plates, microarrays have been used to miniaturize the detection process, 
demanding less material while maintaining high specificity and selectivity. Since the first 
publication on microarrays, where the grid was a 1x1 cm grid with 400 individual spots, the 
grids have somewhat expanded in size while the number of spots has increased 
significantly.18 
Binding events can be DNA or RNA binding for the determination of a mutation 
such as a single nucleotide polymorphism (SNP). This approach also allows for multi-drug 
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screening, in which many drugs of interest are screened against a targeted protein. In the 
same vein, protein-protein binding can also be evaluated such as antigen typing and epitope 
(antigen recognition domain) and surface protein determination can also be evaluated. In 
general, the binding event produces an optical signal, typically a change in intensity, which 
is then read to determine the level of binding.  
Generally, this technique involves three or more steps and at least a half a day to run 
one experiment from sample prep to signal output. The central technology is a 2D array on a 
surface such as glass or thin-film silicon, where the capture molecule is bound to the surface. 
A sample of interest is then applied to the array. If the purpose of the experiment is 
sequencing DNA or RNA, the nucleotides must first be extracted from the source, which 
typically requires the lysing of cells followed by centrifugation for the elimination of any 
other molecules. If instead, a whole cell is used, e.g. for surface protein detection, no such 
preparation is required. In either case, after application of the sample to the array, an 
incubation period is required to ensure binding. Then a wash step is performed to remove 
any non-binding material. The final requirement is the introduction of some sort of optical 
reporter to determine the level of binding, which requires additional application and wash 
steps before detection. A fluorescently labeled antibody can be used in protein and certain 
small molecule detection assays. DNA and RNA probes are often labeled with dyes before 
being added to the array. Finally, detection of the optical reporters is performed to determine 
which spots indicate binding events. This information is used to deduce which mutations, 
proteins, or types of cells were present in the sample. 
There are many examples of the use of microarrays in point-of-care technology 
because they provide the sensitivity and selectivity required from testing with a multiplexed 
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approach. This includes testing such as a lateral flow allergen microarray19, protein 
microarray for neonatal sepsis diagnosis20, and detection of mutations in KRAS and p53 
genes21. These assays detect specific antibodies, non-antibody proteins, protein-protein 
interactions, cell surfaces, and DNA or RNA sequences all while using small volumes of 
reagents. Nonetheless, these assays are complex and time-consuming, requiring multiple 
reagents, washing steps, require the use of expensive readers, and specialty spotting 
instruments. Although the scientific community is combating expensive readers by coding 
programs for cell phone cameras, there has been no improvement speeding up the required 
steps to get to optical detection. 
 
1.1.2 Polymerase chain reaction (PCR) 
Polymerase chain reaction, or PCR, is currently the gold standard for detection of 
DNA or RNA strands and fragments. This method relies on specific instrumentation, 
reagents, and energy to heat and cool the system for the replication of DNA or RNA to 
occur. The technique involves five steps, with a half day often required just to perform the 
amplification. Depending on the detection method employed, an additional half-day or more 
is often needed before detection can be reported. The first step  in PCR is designing primers, 
short DNA sequences that attach upstream of the sequence of interest and allow the DNA or 
RNA polymerase protein complex to bind and begin replication. Once the proper primers, 
Taq polymerase (from Thermus aquaticus), nucleotides, and buffer are added, the reaction 
solution, it is heated to 95 °C to denaturation the double stranded oligonucleotides. The 
solution is then cooled to just below 70 °C to allow primers to anneal to the target strands. 
The solution is then heated slightly to 72 °C, enabling the extension of the primers by the 
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polymerase, which creates copies of the target. These heating and cooling steps make up one 
cycle, which is repeated around 30 times to amplify enough of the target for detection. The 
final step is the detection of the amplified oligonucleotide. This can be a simple gel 
electrophoresis if only based on molecular weight; however in the case of disease 
determination, each base requires sequencing for the accurate diagnosis.  
There are many variations on the method described above for increased specificity, 
and target validation; however, none have achieved applicability for point-of-care. One 
method, helicase-dependent PCR, eliminates the need for thermocycling but requires a 
second protein, increasing the price of the method and requiring optimized buffers and 
primers to produce reliable results.  
Some adjustments have been devised to make the required instrumentation suitable 
for point-of-care. A major focus has been on creating smaller and less expensive versions of 
the thermocycler, undoubtedly a crucial instrument in this method. With low-income areas 
in mind, Walker and coworkers were able to create a thermocycler from a computer.22 Even 
so, the PCR method still requires expensive reagents, time, and skilled workers.   
 
1.1.3 Enzyme-linked immunosorbent assay (ELISA) 
The enzyme-linked immunosorbent assay, or ELISA, is the current gold standard for 
the detection of protein biomarkers.23 This technique is ideal for research or clinical 
situations where skilled workers perform the testing in controlled environments with all 
reagents readily available. Since workers perform these experiments for the detection of 
proteins, which are often present in low concentrations, this technique requires the use of 
long incubation times and many wash steps to ensure specificity. 
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Generally, the ELISA technique requires a minimum of three steps, each with an 
incubation time between 2 and 16 hours. It is typically performed in 94-well plates where a 
control can be performed at the same time as the samples. In the first step, the target is 
exposed to the surface and allowed to adhere, often through non-covalent binding. 
Sometimes an additional step to pre-modify the surface for the target attachment is required. 
For example, in sandwich ELISAs, an antibody specific to the target is adhered to the 
surface before the sample with the target is presented. Once the target has bound to the 
surface of the plate, a wash step is performed to remove excess solution, and remove other 
proteins, not of interest. In the second step, another target-specific antibody is added to 
sandwich the target. A second wash step is performed to again remove any antibody not 
bound to the target. The final step is the reporting method. This can be a fluorescently 
modified antibody used in step 2, or a secondary antibody that recognizes and binds the first 
antibody, and is covalently modified with a fluorescent reporter or the enzyme horseradish 
peroxidase (HRP). In the latter case the enzyme converts hydrogen peroxide into a colored 
solution and the enzymatic reaction is stopped with sulfuric acid.  
A well-developed ELISA method is specific and sensitive but severely user-
unfriendly because it is time-consuming and requires many reagents. In addition, while 
ELISA ultimately works well, each new target requires significant development of buffers, 
washes, incubation times, and antibodies to achieve consistent and reliable results.  
 
1.2 The Rise of Aptamers 
While the methods involving ELISA, PCR, and microarrays demonstrate their 
abilities of detecting small quantities of a target with high specificity, they all also require 
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time-consuming steps with multiple specialized reagents, wash steps, and complex, 
expensive equipment. This section describes how aptamers offer a potentially valuable step 
forward in molecular diagnostics, providing a means for reducing the time needed for time 
to detection, the number of reagents required and the overall cost, while maintaining 
specificity and sensitivity. 
 
1.2.1 Aptamer Background 
Aptamers are single stranded nucleotide sequences that bind a variety of targets from 
small molecules to large proteins with high specificity and selectivity. Advantageously, 
these sequences are small, thermally stable, and inexpensive to synthesize. Aptamers also 
outperform other systems in single-step sensing platforms by undergoing large-scale 
conformational changes that generate a specific output signal. By contrast, however, 
aptamers with high specificity against a target can be difficult to experimentally create and 
their functionality in often condition-dependent.   
Aptamer are identified, rather than rationally designed using the Systematic 
Evolution of Ligands by Exponential Enrichment (SELEX) method pioneered by Tuerk and 
Gold.24 In the first step of SELEX, a large DNA or RNA library of 1015 or more individual 
sequences, are incubated with the target molecule. Sequences are then separated by washing 
away non-binding sequences. Compatible, bound, sequences are eluted under more stringent 
conditions, amplified, sequenced, and prepared for a subsequent round of selection. In 
addition to multiple rounds of positive selection, a negative selection based on a derivative 
of the target is used to increase specificity by eliminating any sequences that bind to the 
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derivative. To create an aptamer, five or more rounds of selection with at least two rounds of 
negative selection are used.  
 
1.2.2 The First Aptamers 
Originally aptamers were created for affinity chromatography to bind both organic 
dye molecules and nucleic acid binding proteins.25 Compared to the standard methods used 
at the time, aptamers were less expensive while still maintaining the specificity required for 
affinity chromatography. These original aptamers were made with RNA bases, and DNA 
aptamers did not arrive until a few years later.26,48 Aptamers were a major improvement to 
methods like ELISA and PCR due to their stability at room temperature and fast binding 
kinetics.27  
DNA aptamers against alpha-thrombin,31 cocaine,28 platelet-derived growth factor 
(PDGF), immunoglobin E, and adenosine triphosphate (ATP) dominate the literature 
landscape.29,30 These aptamers are among the original aptamers and are robust systems used 
repeatedly across the scientific community.31 Research groups often use one of these 
aptamers as a model system for proving new technologies and methodologies.  
With increasing numbers of scientists working in the aptamer field, single targets 
started seeing multiple aptamers. For example, alpha-thrombin currently has two unique 
aptamers. The first, a fifteen-base aptamer, creates a g-quadruplex upon binding with the 
protein at an allosteric site.32 A g-quadruplex is a structure in both DNA and RNA where 
four guanine bases associate through Hoogsteen hydrogen bonding to form a square planar 
shape. This structure can be created from one strand, or many strands where the backbone 
can be either parallel or anti-parallel.33 Two or more g-quadruplex structures can stack on 
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top of each other as seen in the 15-base alpha-thrombin aptamer, which has a stack of two.34 
A second, twenty-seven-base aptamer against thrombin includes both the g-quadruplex 
structure and a stem and binds a different allosteric site on thrombin, such that it resembles a 
candy cane shape; the g-quadruplex being the hook and the stem wrapping itself down the 
long part of the candy cane.35 Some researchers have used both alpha-thrombin aptamers to 
identify the protein at lower concentrations allowing for better detection.36,37 Another 
advantage of using two aptamers is the allowance for a sandwich-like assay in which the 
first aptamer can be attached to a surface for capturing the protein, and the second aptamer 
can be used for detection with an optical reporter. This constitutes an extension of the 
ELISA method with antibodies replaced by aptamers.38 Since aptamers require shorter 
binding incubation times than antibodies, their use speeds up the time to diagnosis. 
 
1.2.3 Aptamers in Diagnostics 
As noted above, the first aptamers were made from RNA. This was due to the recent 
discovery of their active participation in cell signaling, not just carrying genetic 
information.39 Many of the attempts at converting RNA aptamers to DNA sequences 
resulted in decreased affinities, even when the structures were nearly identical.40,41 Although 
it is rare that an aptamer directly converted from RNA to DNA performs identically, the 
dopamine aptamer held all of its properties.42 Also, as noted previously, aptamer affinities 
are notoriously dependent on the conditions of the experiment, which include the backbone 
of the aptamer for binding the target of interest.43 
The use of aptamers in diagnostics proves difficult when using real samples of serum 
or whole blood, or working directly in in vivo. Proteins within these solutions rapidly break 
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down the oligonucleotides by hydrolyzing the bases, thereby eliminating the aptamer and its 
ability to detect the target of interest. Various modifications are made to aptamers to prolong 
their life in diagnostic samples, however that is not the focus here.43  
With the discovery of aptamers, efforts to harness them for diagnostic purposes 
bloomed. One example is a qualitative lateral flow test for cocaine.44 In this test, 
streptavidin-coated gold nanoparticles (AuNP) are additionally coated in the cocaine 
aptamer, and allowed to aggregate. The aggregation of AuNPs produces a distinct red color. 
In the presence of cocaine, the aptamer folds around its target and disassociates from the 
AuNPs. The dis-aggregated AuNPs then flow through a filter binding to a biotin strip, 
creating a red line. This test is able to function in complex solutions such as saliva, urine, 
and blood serum due to the filtering nature of the lateral flow strip. Another example uses 
both AuNPs and quantum dots (QD) to detect both cocaine and adenosine independently in 
the same sample.45 Here, the aptamer is conjugated to the QD, and a hybridizing strand is 
conjugated to AuNPs. When the solutions are mixed, a low luminescence is observed as a 
result of the hybridization of the aptamer with its hybridizing strand, bringing the QDs and 
AuNPs in close proximity to one another. Upon addition of the target, the aptamer folds and 
releases the hybridizing strand, thereby separating the complex and resulting in high 
luminescence. By conjugating the cocaine aptamer and the adenosine aptamer on QDs with 
different wavelengths, one solution can independently determine either target. This system 
performed well in 10 % serum but required overnight incubation for best results.  
Another use of diagnostic aptamers is the labeling of malignant cells. The protein 
mucin (MUC1) is a glycoprotein found on epithelial cells. While present on healthy cells, it 
is expressed in 10x higher concentrations on extracellular membranes of in cancerous cells. 
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The use of aptamers rather than antibodies for labeling in vivo allows for a much faster 
clearance of unbound probes. Non-binding antibodies take a time to clear from the cells, 
extending the time required for accurate detection. The aptamer against MUC1 can be 
modified to include a mercaptoacetyl diglycine (MAG2) ligand which complexes with 
technetium.46 When this aptamer complex is loaded with radiolabeled 99Tc, it can be injected 
into mice where the aptamer will detect the MUC1 glycoprotein. To determine the organs 
where MUC1 has mutated, the detection of gamma-rays is performed in a scintillation 
counter.47  
 
1.3 Structure-Switching Aptamers 
As their name suggests, structure-switching aptamers are dynamic and transition 
between two different structures. One structure does not bind the target while the other does. 
As such, target binding causes a conformational change. The first example of the use of 
structure-switching aptamers comes ten years after the appearance of aptamers in 
literature.25,73 An advantage of this type of aptamer is that it allows for direct detection of 
target when using an output such as fluorescence. Thus, the binding of the target of interest 
creates a signal from the aptamer that reports on the concentration of the target in a solution.  
The first use of a structure-switching aptamer was reported in 2001 when Hamaguchi 
and co-authors described the use of the 15-base thrombin aptamer as a starting point.48,73 
They modified the aptamer by adding 4 to 6 added bases to produce a stem-loop structure in 
the absence of thrombin. These added bases bind the middle of the g-quadruplex, disrupting 
both the quadruplex structure and protein binding. With this new aptamer, the researchers 
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were able to detect thrombin at an apparent disassociation constant of 10 nM, a vast 
improvement over the original 200 nM. 
Since 2001, the use of structure-switching aptamers has increased. Luminescence the 
detection of immunoglobulin E (IgE),49 and fluorescence detection of platelet-derived 
growth factor (PDGF),50 cocaine,51 and adenosine triphosphate (ATP)52 have all been 
achieved using structure-switching aptamers.  
During SELEX, aptamers can be designed to unbind a sequence upon target binding. 
In this system a small sequence, between 7 and 15 bases is added for hybridizing another 
DNA strand. This sequence is placed in the middle of the DNA library so that upon binding 
to the target the hybridization is disrupted. To create a signal-on structure-switching 
aptamer, a quencher is added to the hybridizing strand. The quencher stays in close 
proximity to the fluorophore when hybridized. Then when the aptamer binds the target, the 
quenching strand is displaced, allowing for increasing fluorescence. Nutiu and Li detail this 
system in the creation of an ATP structure-switching aptamer after performing 16 rounds of 
selection.53 
 
1.3.1 Designing Structure-Switching Aptamers 
In the absence of explicit selection for structure switching, not all aptamers switch 
between non-binding and binding conformations. To create a direct-detection, structure-
switching aptamer modification from a parent sequence is preferred. This design effort can 
prove easier if it is known how the aptamer binds its target, but a number of methods 
demonstrate proficiency even in the absence of this information. 
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Naturally, understanding the target-binding region of an aptamer sequence provides 
insight into the system. Aptamers are raised with primer tails on either side of a sequence to 
enable amplification. These primer sequences can inadvertently be involved with target 
binding. Most selections performed today take precautions to ensure primers are not 
involved with binding. Truncation studies aid in determining the sequence required for 
binding. Although any change in sequence could result in a decrease in binding affinity 
between the aptamer and the target, performing truncation studies in a logical manner helps 
maintaining the best binding affinity. Regardless, aptamers are often reported with primers 
and with only limited truncation studies. 
Ideally, a co-crystallization or nuclear magnetic resonance (NMR) resolved structure 
of the aptamer and its target will accurately determine the binding location. While this is 
easier with small molecules, as they are small and more static, there are instances of well-
established aptamers that have no crystal structure. Generally, enzymes are difficult to 
crystallize without a cofactor to hold the enzyme in a static state, and as such, there are only 
a few enzyme-binding aptamers co-crystalized with their target.54 Additional challenges in 
crystallizing the target with the aptamer arise are due to the flexibility of aptamers the 
unbound state. 
 
1.3.2 Additional Oligonucleotides for Detection 
In a second approach to inducing aptamers to switch between two structures, 
additional oligonucleotide strands were added and designed into the system.55 As mentioned 
previously the fluorophore and quencher are on separate strands rather than contained in the 
same strand. Upon target binding, the second strand is displaced, separating the fluorophore 
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and quencher, thus producing fluorescence. Another option is to split the aptamer into two 
different strands that only come together upon binding of the target. In this system, a 
decrease in fluorescence is seen when using a fluorophore and quencher, or a change in 
fluorescence emission wavelength is seen with overlapping fluorophores. 
Alternatively, a quenching strand added to the aptamer for hybridization can also 
cause structure switching. Chen et. al. used this method with their aptamer for ochratoxin A, 
a food-born toxin.56 The 36-base fluorescein-labeled aptamer was hybridized to a quencher-
labeled strand of nine to thirteen bases. In addition, the authors looked at the ratio of the 
aptamer to quencher strand to optimize the system. In the end, they used the 10-base 
quenching strand with a 1:3 ratio of the aptamer: quenching strand in real corn samples. 
The addition of these extra oligonucleotides vastly improved the variety of aptamers 
able to directly detect the binding of the target. However, such additional oligonucleotides 
only add to the number of reagents required to produce results. As WHO guidelines 
recommend point-of-care testing be as user-friendly as possible, additional reagents for the 
simple detection of a target is sub-optimal. This type of aptamer system was included here 
however as a stepping-stone to systems with internal controls, as explained in the next 
section.  
 
1.3.3 Internal Controls for One-tube Detection 
As per the WHO strategy for point-of-care testing, rapid testing helps ensure that a 
patient obtains the advice and treatment indicated by the test. To make testing rapid, the use 
of complex solutions is required. As aptamers are susceptible to degradation in these 
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complex solutions, the employment of an internal control is needed to ensure accurate 
detection of the target. 
One example of the use of an internal control comes from the Yingfu Li group in the 
detection of theophylline in human serum samples.57 The system requires the use of four 
strands as follows. The first strand is the aptamer, with additional bases for binding the other 
strands. The second strand hybridizes to the aptamer section of the first strand at the 3’ end 
and contains a quencher at its own 3’ end. The third strand sits in the middle of the first 
strand and presents two different fluorophores on each end. Finally, the fourth strand 
hybridizes to the 5’ end of the first strand with a quencher on its own 5’ end. This set up 
allows the first fluorophore to fluoresce upon the binding of the target. However, a false 
positive occurs if the second fluorophore signals indicating endonuclease activity through 
the cleavage of the strands. While this internal control provides identification of 
endonuclease activity on the aptamer, there could still be changes in fluorescence from 
sample to sample with no way to accurately compare the target concentrations between 
samples.  
Our group pushed these established boundaries to include internal controls that could 
account for sample variation. Vallée-Bélisle et al. used a DNA sequence to detect 
transcription factors, proteins that recognize double-stranded DNA to initiate the 
transcription of DNA into messenger RNA (mRNA).68 In addition to this transcription factor 
aptamer, a competitor and stabilizer strand were used. The competitor strand binds the target 
transcription factor, removing the target from the aptamer. This returns the aptamer to the 
baseline fluorescence. The stabilizer strand binds the aptamer in the target binding form, 
such that maximum fluorescence is achieved with no added target. With these three 
  18 
measurements the concentration of an unknown amount of target can be determined, 
regardless of the variation in background fluorescence from the sample. In addition, the 
three measurements can be performed one after the other in a single tube. In addition to 
performing this work in buffer, experiments were extended to quantify transcription factors 
in cell extract solutions. 
The goal of the work presented here is to extend these structure-switching aptamers 
to include a universal approach for creating this internal reference system with only three-
steps for the quantification of various targets in additional complex solutions.  
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Chapter 2. Molecular Beacon Aptamer in a Tube 
2.1 Introduction 
Recent years have seen the development of a wide range of biosensors that employ 
binding-induced conformational changes in an oligonucleotide-based “receptor” to 
transduce molecular recognition events into easily detectable optical,58 electrochemical,59 
microgravimetric,60 or electronic61 readouts. Examples include the use of DNA oligomers 
and aptamers attached to reporting agents such as Quantum Dots (QD),62, 63 gold 
nanoparticles,64, 65 gold surfaces,66, 67 and fluorescent labels.68 The advantages of these 
sensors include high specificity, low binding affinities, and quantitative detection, all while 
remaining wash-free and single-step. This suggests that they may prove promising as an 
approach to inexpensive, point-of-care molecular diagnostics.  
Despite the potential advantages of beacon-type sensors, the use of these 
conformation-linked fluorescent sensors is complicated by the procedures needed to 
calibrate their response in complex sample matrices. For example, the background 
fluorescence arising from interferents and modulation of the beacon’s fluorescence due to 
absorbance or quenching can vary from sample to sample and must be carefully corrected. 
Signal gain, the maximum signal that would be expected at saturating target, can likewise 
vary from experiment to experiment due to changes in the concentration of the beacon or 
sample conditions. Given these complications, beacon-type approaches rely on the use of 
sample blanks to determine baseline signals and the addition of saturating target to 
determine signal gain. Good blanks, however, can be difficult to obtain if, for example, 
patient-to-patient variations in blood composition are so significant that the blood of one 
subject cannot be used as an accurate blank for another. The use of saturating target to 
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determine a beacon’s signal gain under authentic sample conditions can likewise be 
expensive or difficult depending on the target.  
Here we demonstrate an approach to beacon calibration that employs three 
inexpensive reagents in a single-tube and three sequential measurements to achieve the 
quantitative determination of an unknown target in a complex sample matrix without the use 
of either blanks or saturating target.  
 
2.1.1 General Approach 
To determine the concentration of a target using a beacon requires knowledge of 
three experimental values. The first is the beacon’s fluorescent output, Ftarget when it is in 
equilibrium with the target in the sample. We obtain this value by introducing the beacon to 
the sample, allowing the system to equilibrate, and then taking the first measurement. In 
order to correlate Ftarget with the occupancy of the beacon (from which, through its known 
disassociation constant, KD, we can determine target concentration. We must also determine 
the signals observed when the beacon is entirely unoccupied in the same sample matrix, 
Fbaseline, and when it is entirely occupied, Fsaturation. To obtain the former we can “swamp” 
the system with a competitor that lacks the optical reporters and thus does not generate a 
signal upon target sequestration. The competitor can be comprised of either the same 
receptor at orders of magnitude higher concentration than the target or a higher affinity 
receptor in nearer stoichiometric excess. This competitor depletes the target molecules in the 
sample, allowing the measurement of Fbaseline. To obtain Fsaturation, in contrast, requires full 
occupancy of the beacon. This can be achieved via the addition of the target molecule in 
large excess over the beacon concentration and, if one is performing a single-tube 
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measurement, also over the concentration of the competitor. For many target molecules, 
however, this can be prohibitively expensive and/or inconvenient.  In response we employ 
beacons that instead allosterically bind a specific “activator” oligonucleotide in a manner 
that mimics the conformational change associated with target binding. Our motivation for 
doing so is that oligonucleotide activators are generally less expensive and more convenient 
(stable and highly soluble) than many of the target molecules of interest.  
Our approach to beacon-based concentration determination is reduced to three 
sequential fluorescence measurements in a single tube (Figure 2.1). First we add the beacon 
to the sample, equilibrate it with the endogenous target, and measure Ftarget. We then add an 
excess of competitor to this same tube, equilibrate again, and measure Fbaseline. Finally, we 
add an excess of the activator, equilibrate a third time, and measure Fsaturation.  These three 
measurements are sufficient to calculate the target concentration as 
 
 𝑡𝑎𝑟𝑔𝑒𝑡 = !! (!!"#$%!!!!"#$%&'$)(!!"#$%"#&'(!!!"#$%!)  Eq. 1 
 
where the KD of the beacon under the comparable conditions has previously been 
determined. As you will see here, each system is dependent on the aptamer, however, the 
concentration ranges are 81x when the aptamer is under the determined KD, and 10x when 
the aptamer is above the determined KD, following the anticipated Langmuir isotherm.  
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Figure 2.1 The three-step, single-tube calibration method for employing beacons in complex sample 
matrices. (Top) In the first step, the sensor is equilibrated with the target in the sample to determine 
Ftarget. Second, we add an excess of unlabeled competitor so as to de-populate the beacon-target 
complex, allowing us to measure Fbaseline. Finally, the addition of an activator is used to simulate 
Fsaturation, the fluorescence that would be observed were the beacon fully occupied. (Bottom) From 
these three measurements and the known disassociation constant of the beacon, KD, we can derive 
the target concentration. 
 
2.2 Results and Discussion 
2.2.1 Molecular Beacon "Aptamer" as a First Model System 
The first system with which we explored single-tube beacon calibration we 
employed the first reported sensor in this class, the “molecular beacon” of Kramer and co-
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workers,69 which is now commonly employed for the detection of specific DNA or RNA 
sequences.70,71,72 Molecular beacons traditionally consist of a simple stem-loop DNA 
modified on its two ends with a fluorophore/quencher pair (Figure 2.2). In the absence of 
target the stem holds these optical reporters in close proximity, quenching fluorescence. 
Hybridization to a complementary target segregates the fluorophore from the quencher, 
increasing fluorescence. For our studies we fabricated a 27-base molecular beacon with a six 
base-pair stem, a tetramethylrhodamine carboxylic acid (TAMRA) fluorophore, and black 
hole quencher (BHQ). The loop of our molecular beacon recognizes 19 bases of a 23-base 
single-stranded target DNA. As a higher affinity competitor we employed a 27-base DNA 
lacking reporters and fully complementary to the target. Finally, as our activator we 
employed a 27-base DNA fully complementary to the molecular beacon, the binding of 
which mimics the binding of the authentic target.  
Our single-tube calibration approach performs well when used with the molecular beacon in both 
simple buffers and more complex sample matrixes. To show this we first determined the beacon’s 
disassociation constant to be 34.8 nM in 3-(N-morpholino)propanesulfonic acid (MOPS) buffer (10 
mM MOPS, 140 mM NaNO3, 10 mM ethylenediamine tetra-acetic acid (EDTA), pH 7.4), and 23.7 
nM in 50% fetal bovine serum in MOPS buffer ( 
Figure 2.3 and Figure 2.4). We then used our single-tube, three-measurement 
approach to determine the concentration of the beacon’s target under both conditions. For 
example, starting with a known, 10 nM target concentration in MOPS buffer our three-
measurement-one-tube approach recovers a concentration of 10.3 nM with a 95% 
confidence range of 8.5 to 12.2 nM. A second test run performed in 50% fetal bovine serum 
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(FBS) also using a 10 nM target concentration produced an answer of 9.1 nM with the 95% 
confidence range from 7.5 to 10.7 nM.  
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Figure 2.2 Single-tube calibration approach as applied to the measurement of the concentration of a 
specific nucleic acid sequence using a molecular beacon. (Top) From left, molecular beacon alone, 
before addition to the sample; upon target addition, target binds the beacon, opening the molecular 
beacon for fluorescence corresponding to concentration of target; addition of the competitor 
sequesters the target, allowing the molecular beacon to adopt the structure of no target present, or 
background signal; following these steps, the addition of activator saturates the beacon producing the 
maximum signal gain.  (Middle) The response of the sensor in buffer with sample (white bars) or in a 
sample-free control (grey bars). Control solutions contain sensor but are not exposed to target. 
Control solutions are challenged with the activator in the last step to ensure the experimental 
saturation signals match that of a control. Calculated target concentration is 10.3 nM. (Bottom) The 
response of the sensor in 50% serum. Bars are the same colors as the middle graph. Calculated target 
concentration is 9.1 nM. All data points are the average value with error bars as standard error (n=3).  
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Figure 2.3 Titration of Molecular Beacon Aptamer sensor in MOPS Buffer. Data points are average 
and error bars are the standard error (n = 3). Langmuir isotherm fit is solid line. 
 
Figure 2.4 Titration of the molecular beacon sensor in 50% fetal bovine serum. Data points are 
average and error bars are the range (n = 2). Solid line is a Langmuir isotherm fit. 
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2.2.2 Silver-binding Aptamer 
Expanding on the molecular beacon framework, Hamaguchi, Ellington and Stanton73 
were the first to report beacon-type sensors employing aptamer recognition elements – DNA 
or RNA molecules selected in vitro for their ability to detect specific non-nucleic acid 
targets – for the detection of proteins, small molecules and inorganic ions.74,75,76 As a test bed 
to demonstrate the adaptation of our calibration approach to these more complex beacons we 
first employed a fairly simple aptamer that binds silver ions. Specifically, the silver ion 
binds between cysteine-cysteine mismatches in double stranded DNA,77 an effect that has 
previously been used for the detection of this target.78,79 
Elaborating on our modified molecular beacon we designed a beacon for the 
detection of silver and tested it in both simple buffer and in creek water samples. This 49-
base beacon contains a fluorescein fluorophore, often abbreviated as FAM or FITC, at the 
26th base, and a black hole quencher (BHQ) at its 5’ end. In the absence of silver the beacon 
adopts a double-stem-loop structure that holds the fluorophore/quencher pair in proximity 
(Figure 2.5). Upon binding silver the beacon rearranges into a single-stem-loop structure 
that separates the pair. As the competitor we employed a 40-base pair stem loop containing 
8 silver-binding C-C mismatches; because this does not undergo a binding-induced 
conformational change its affinity is significantly higher than that of the beacon. As an 
activator, we employ a 14-base element complementary to the 3’ end of the beacon. 
Hybridization of the activator with the beacon opens the beacon in a manner that mimics the 
silver-bound conformation. However, when the activator is added, the beacon produces 
consistently lower fluorescence than saturating silver fluorescence. To correct Fsaturation, the 
observed value is multiplied by 5/3. The disassociation constant of the beacon is 200 nM in 
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MOPS buffer and 51 nM in an environmental sample (creek water) diluted 50:50 with 
MOPS buffer (lowering the ionic strength alters the KD) (Figure 2.6 and Figure 2.7). Using 
our one-tube three-measurement approach with a known target of 50 nM in MOPS buffer 
we recover a 46.6 nM silver ion concentration with a 95% confidence range of 39.7 to 53.4 
nM. A second run using 50% creek water/50% MOPS buffer with a known target 
concentration of 20 nM recovers a concentration of 19.1 nM with a 95% confidence range of 
11.2 to 27.1 nM.  
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Figure 2.5 The measurement of silver ions using a beacon containing silver-binding C-C 
mismatches. (Top) Visual representation of the step-wise addition for the silver(I) ion detection 
system. From left, silver beacon alone, before addition to the sample; upon target addition, target 
binds the beacon, opening the two-stem architecture to a one-stem molecular beacon for fluorescence 
corresponding to concentration of target; addition of the competitor sequesters the silver ion, 
allowing the beacon to adopt the structure of no target present, or background signal; following these 
steps, the addition of activator binds to the beacon producing the maximum signal gain, equivalent to 
target saturation. (Middle) The response to sensor upon step-wise addition of the target in MOPS 
buffer. Bars in white are solutions exposed to samples, while grey bars are control solutions with 
sensor, but only exposed to activator to ensure replication. (Bottom) The response of the sensor upon 
step-wise addition of target in 50% creek sample. All data points are averages with error bars as 
standard error (n=3). Sensors were tested in creek water samples as silver(I) ion is toxic to fish in 
streams at levels above 2.5 nM, depending on fish species and size.80, 81 .  
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Figure 2.6 Titration of the silver ion sensor with silver ion in buffer. Data points are averages and 
error bars are standard errors (n=4). Error bars are obscured by data points. Solid line is Langmuir 
isotherm fit. 
 
Figure 2.7 Titration of the silver ion sensor with silver ion in creek sample. Data points are averages 
and error bars are the range (n=2). Error bars are obscured by data points.Solid line is Langmuir 
isotherm fit.  
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2.2.3 Thrombin Aptamer 
As a final test system we adapted our approach to the 15-base thrombin-binding aptamer of 
Hamaguchi, Ellington, and Stanton.73 Here we added a 10-base tail to the 3’ end of the aptamer such 
that the lengthened construct forms a stem-loop in the absence of target (Fig. 4). To determine the 
best location of the fluorophore for the best signal change upon thrombin binding, two architectures 
were created. The first, thrombin structure-switching aptamer 1 (TSSA1) has the fluorophore at its 5’ 
end, and the quencher at the 3’ end. The second, thrombin structure-switching aptamer 2 (TSSA2), 
was made with the fluorophore attached to thymine five bases from the 5’ end, and retaining the 
quencher on the 3’ end. Both aptamers fold into a molecular beacon, or stem-loop architecture, 
bringing the fluorophore/quencher pair into proximity. Upon thrombin binding the aptamer folds into 
a g-quadruplex, segregating this fluorophore/quencher pair, increasing fluorescence (Figure 2.8 and  
Figure 2.9). Indeed, the TSSA2 sensor, with a closer fluorophore/quencher pair, 
creates a larger change in signaling (Figure 2.10). Although this change is larger, the overall 
fluorescence is lower, most likely due to the close proximity of the pair, and may prove 
inhibitory upon use in serum. The experiments further detailed here all employ the 
architecture, named TSSA1, with the fluorophore at the 5’ end of the sensor. 
As competitor we employed the original 15-base aptamer with a 10 base poly-T tail. 
Thus the competitor does not form the stem-loop and possesses a higher affinity for 
thrombin than the beacon. As an activator we employ a 25-base construct complement to the 
full length of the beacon. Other lengths of activators were tested, however none proved to 
create the same saturating signal as the 25-base activator (Figure 2.11). 
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An investigation of this system revealed a KD for the thrombin aptamer with human 
thrombin in buffer (10 mM Tris, 7.4 pH), of 16 nM (Figure 2.12). A singular experiment to 
determine an unknown concentration of thrombin was performed (Figure 2.13). From this 
experiment, the determined target concentration of 12 nM was significantly smaller than the 
spiked concentration of 20 nM thrombin. This experiment needs to be repeated in the future 
to determine accurate target concentrations.  
Finally, in anticipation of challenging the system in blood serum, the sensor was 
tested against bovine thrombin. Although the aptamer was created to solely recognize the 
human thrombin, bovine thrombin is similar, differing by only few amino acids. Most 
importantly, there is only one amino acid different in the binding site of the aptamer. In 
Figure 2.14, increasing concentrations of bovine thrombin (bThrombin) are added to the 
sensor with some increase in fluorescence. As compared to the same sensor binding to 
human thrombin (hThrombin) however, the fluorescence increase is almost insignificant: 
hThrombin causes a 200% increase in signal while bThrombin only causes a 50% increase.  
In future experiments, this three-step system must be completed. To fully complete 
the system as the molecular beacon and silver aptamer were completed, there are several 
required experiments. First, completing the stepwise sample concentration as described 
above with an accurate determination will allow the system to move forward to serum 
experimentation. While preparing the system for accurate target determination in serum 
solutions, any background bThrombin binding must be quantified. An experiment using the 
method of standard additions can quantify bThrombin in any fetal bovine serum before 
quantifying any spiked additions of hThrombin.  
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Figure 2.8 Measurement of thrombin protein with the thrombin aptamer. From left, thrombin beacon 
alone, before addition to the sample; upon thrombin addition, thrombin binds the sensor, opening the 
molecular beacon for fluorescence corresponding to concentration of target; addition of the 
competitor sequesters thrombin, allowing the beacon to adopt the structure of no target present, or 
background signal; following these steps, the addition of activator binds to the beacon producing the 
maximum signal gain, equivalent to thrombin saturation.  
 
Figure 2.9 Titration of thrombin aptamer with hThrombin. This aptamer has the fluorophore on the 
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Figure 2.10 Titration of hThrombin with Thrombin Aptamer. This aptamer has the fluorophore 
inserted between the 5th and 6th base from the 5’ end with the quencher at the 3’ end (TSSA2). Each 
scan is the average of 2 scans. 
 
Figure 2.11 Time kinetics of various sized activators upon addition to the TSSA1 aptamer. 
Activators were added at 2 minutes, and data points were taken every 15 seconds.  
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Figure 2.12 Titration of hThrombin with the Thrombin aptamer TSSA1. Data points are the average 
with error bars as the standard error (n=3). Fitted line is a Langmuir isotherm for KD determination 
of 16 nM. 
 
Figure 2.13 Concentration determination of hThrombin using the stepwise addition. Red bars 
indicate the control solutions with the TSSA1 aptamer with no target addition, but activator is added 
at the end. Blue bars indicate experimental solutions taken through the step-wise addition. All data 
bars are average with error bars as the range (n=2).  
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Figure 2.14 Titration of bThrombin and hThrombin with the Thrombin aptamer TSSA1. Data points 
reflect averages with error bars as the range (n=2). 
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As all projects go, not all perform optimally. The following examples were 
predecessors to the MBA, silver(I) ion, and thrombin aptamer systems. Each had its 
complications, from which lessons were learned to create the working three-step system. 
They are included in this thesis as documentation for future researchers. 
 
2.2.4 PfLDH Aptamer 
In beginning this project, the goal was to select an aptamer with relevance to the 
point-of-care world from literature. Additionally, the aptamer should have enough literature 
support to ensure repeatability and detail the location of aptamer binding to its target. These 
two requirements would allow for changes to the aptamer sequence with additions to create 
a structure-switching architecture.  
This aptamer was found in the journal abbreviated PNAS with a co-crystallized 
structure of the protein and the created aptamer.82 One appealing feature of this aptamer was 
its target, the lactose dehydrogenase protein from the malaria-causing protozoan parasite 
Plasmodium falciparum (PfLDH). The researchers determined that the aptamer detection of 
the malarial LDH was specific, and does not detect human LDH. A second appealing feature 
was the co-crystallization with the target molecule, providing an optimal way of tweaking 
the aptamer sequence with out reducing interactions between aptamer nucleotide bases and 
the protein.  
While studying the aptamer-protein co-crystallization in the paper, the 27-base 
sequence important for binding forms a loose loop with some making hydrogen bonds. 
Additionally, the PfLDH protein is made of 4 subunits, with two aptamers binding between 
subunits A and B, and C and D. While studying the architecture of the aptamer, an important 
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flipped base at the 16th position (an adenine) from the 5’ end shows interaction with the 
protein. Finally, the aptamer has an eight base sequence on the 3’ end that could be used as a 
tail. 
To create a structure-switching aptamer where the binding conformation turns 
fluorescence on, the loop that binds the protein must be hidden in the off state (Figure 2.15). 
To accomplish this, a tail on the 3’ end of the aptamer binding sequence was created to bind 
the middle of the loop. This replaced the eight non-binding bases in the original aptamer. On 
each end of this newly created stem loop, a fluorophore and quencher were inserted into the 
sequence, such that fluorescence would be quenched in the non-binding form, and 
fluorescence would increase upon binding. 
The final modification to the aptamer sequence added six bases on both the 3’ and 5’ 
ends of the sequence to act as toeholds for the stabilizer. Previously a stabilizer sequence 
held the sensor in the binding state with maximum fluorescence.68 
Proteins PfLDH and human lactose dehydrogenase b (hLDHb) were acquired from 
the Tanner group, with frozen stock of PfLDH, and vectors for both PfLDH and hLDHb. 
Some primary experiments were performed using the frozen stocks of PfLDH while more 
protein was grown and purified. 
The primary experiments showed decreases in fluorescence upon increasing PfLDH 
protein concentration. When challenged with a non-binding protein, bovine serum albumin 
(BSA), there was no change in fluorescence (Figure 2.16). 
Upon analysis of the results along with the cartooned aptamer, it was determined that 
the fluorophore was interacting with the protein upon binding causing a decrease in 
fluorescence. Additionally, the initial fluorescence from the sensor suggested that the non-
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binding state was not achieved such that the fluorophore and quencher were not in close 
enough proximity. 
 
Figure 2.15 Cartooned structures of the PfLDH aptamer. 5’ end is on left hand side in both drawings. 
Blue bases are the binding sequence to the protein. Red base is the flipped out base, also involved in 
binding. Fluorescein (FAM) is the fluorophore and BHQ is the black hole quencher. (Left) 
Nonbinding state, fluorophore and quencher pair are close in proximity. (Right) Binding state with 
the blue bases presented in the loop. Fluorophore and quencher pair are separated in this architecture, 
resulting in fluorescence.  
 
Figure 2.16 Titration of PfLDH aptamer with PfLDH protein and BSA as a negative control. Closed 
circles are challenged with PfLDH protein, open boxes are BSA challenged sensors. Data values are 
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2.2.5 H6 Aptamer 
After the PfLDH aptamer did not provide a pathway to a possible aptamer system, 
another aptamer was chosen from literature. The histidine tag aptamer was chosen from the 
Weihong Tan group, known for the development and use of aptamers. This aptamer targets 
the histidine tag added to the N terminus of proteins and was developed as a second 
generation in the Tan group from the original sequence patented in another form by Sharon 
Doyle and Michael Murphy.83,84 The basis for choosing a histidine tag aptamer would also 
allow for detection of proteins within cell lysates. Although the aptamer would not be 
specific for a protein, it is rare to have more than one protein with a histidine tag within a 
bacterial culture, as this would not allow for purification. Here, I named the aptamer “H6 
aptamer”, for the six-histidine amino acids added to proteins as a tag for purification.  
In the first experiments, the aptamer was challenged against the hLDHb protein. 
Since I personally prepared this protein, from growth through purification, it was a solid 
starting point. Additionally, the purification required a nickel column for the added his-tag. 
As seen in Figure 2.17, there was no change upon increasing amounts of hLDHb protein. A 
second protein, a commercially available his-tagged H1N1 recombinant protein was used to 
challenge the H6 aptamer. Due to the higher stock concentration, this protein allowed for a 
larger range of added his-tagged protein. As seen in Figure 2.18, the aptamer continued to 
not respond to known his-tagged proteins.  
From these two negative responses to known histidine tagged proteins, this project 
was stopped. When looking retrospectively at this project, the aptamer did not have citations 
from other groups, which can reduce the aptamers reproducibility. Compared to the Tan 
group aptamer structure, the polyethylene glycol (PEG) spacer was removed, resulting in 
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possible higher rigidity and reduced ability of the aptamer to bind a histidine tag. All that 
said the original patented aptamer did not contain any spacers, so it is unlikely that the 
deletion of the PEG spacer caused the aptamer to detect his-tags.  
 
Figure 2.17 Titration of H6 aptamer with added hLDHb protein. Data points are averages and error 
bars are the range. (n=2). 
 
Figure 2.18 Titration of H6 aptamer with added H1N1 recombinant protein. Black circles are with 
the recombinant protein while the open squares are control solutions with no added target. Data 
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2.2.6 Mercury Ion Aptamer 
With two systems not working according to the goals of the project, literature was 
combed through to find aptamers used by at least two groups. The mercury(II) ion aptamer, 
or a thymine-thymine mismatch, had been used by many groups, including our own.85,86,87 
Instead of using the aptamer in a cooperative manner as many of the previous groups, a new 
sequence was produced with a singular thymine-thymine mismatch (Figure 2.19).  
Upon completing many titrations, a problem arose at the higher concentrations of 
mercury chloride, a decrease in the overall fluorescence (Figure 2.20). Based on a literature 
search, heavy metals with f orbitals, such as mercury(II) could be interacting with the π 
orbitals of the fluorophore, and therefore acting as a quencher in solution. Even with lower 
concentrations titrated into solution, a plateau is not formed and rather decreases in 
fluorescence are seen, even at lower concentrations than when a wide concentration is 
performed (Figure 2.21). Further supporting this hypothesis of mercury (II) ion interfering 
with fluorescence was the addition of the mercury competitor, which caused a 20x increase 
in fluorescence. This increase in fluorescence could only be due to the capture of mercury 
ions in the competitor thymine mismatches, removing any interaction in solution to the 
fluorophore.  
To also show that there is no quenching of fluorescence by heavy metals without f 
orbitals, silver (I) ion was added at increasing concentrations to a solution of the mercury 
aptamer (Figure 2.22). There was no decrease in fluorescence, instead however, there was an 
increase in fluorescence. With this knowledge, focus moved from the mercury ion aptamer 
to the silver ion aptamer. 
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Previous groups using the mercury aptamer were able to get around the quenching 
problem with mercury (II) due to the cooperativity of their sensors allowing for lower 
binding affinities. As we were interested in studying single binding events, this eliminated 
this sensor from being used in our project. We learned that heavy metals with f orbitals 
could contribute to fluorophore quenching at high concentrations. 
  
  44 
 
Figure 2.19 - Single mercury (II) ion molecular beacon aptamer. The non-binding state (left) is the 
energetically favorable state, and is kept in that state until mercury (II) ion is present. Sequence in 
blue shows the stem that forms in the presence of mercury (II) ion (right). Fluorescein is attached to 
the thymine (green circle), and onyx quencher A is at the 3' end (black circle). 
 
 
Figure 2.20 Titration of mercury(II) with 10 nM Mercury Aptamer. At higher concentrations of 
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Figure 2.21 Titration of mercury (II) ion with mercury aptamer at lower concentrations. Decreases in 
fluorescence seen above 100 nM. Data points are averages and error bars are standard deviation (n = 
3).  
 
Figure 2.22 Titration of Silver (I) ion with the mercury aptamer as a demonstration that silver ion 
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2.3 Conclusions 
Here a novel approach has been described to perform calibrated molecular and 
aptamer beacon measurements. This approach is suitable for the quantification of targets 
even in complex sample matrices, which requires only three sequential measurements that 
are performed in a single tube. Further adding to its convenience, only inexpensive DNA-
based reagents are required, obviating the need for the addition of saturating target to obtain 
an upper baseline for the measurements. I believe this technique can be universally applied 
to any target system, regardless of previous difficulties. The quantification of a target using 
this three-step system was proven through the detection of three different systems, a DNA 
strand, a small ion, and a protein.  
Further work is necessary to completely show the thrombin aptamer works in serum 
samples. Although the groundwork and the path forward are provided, the experiments must 
be completed to fully show the aptamer working in the three-step system.  
Should an additional aptamer be designed for the use in the three-step system, it is 
important to consider the binding of the aptamer to the target, the possibility of disrupting 
this binding with a second structure, and how an activator can be designed to mimic binding 
of the target at saturation. Serum has a high autofluorescence in the blue-green range, 
therefore, a fluorophore that excites in the red region will out-perform one in the green or 
yellow range. Furthermore, solution autofluorescence will be of great importance for future 
aptamer designs with the intention of using them in a complex solution.  
 
  47 
2.4 Experimental 
2.4.1 Materials 
HPLC purified DNA sequences for MBA and mercury ion aptamers were ordered 
from Sigma-Aldrich (Woodbridge, MO), all other HPLC purified DNA sequences were 
ordered from Biosearch Technologies (Novato, CA). All DNA stock solutions were made to 
100 µM using UltraPure distilled water (Gibco, Grand Island, NY; now Thermofisher 
Scientific) and stored at 4 °C in their original packaging. Mercury (II) chloride, silver 
perchlorate, 3-(N-morpholino)propanesulfonic acid (MOPS), BL21 (DE3) pLysS-T1 
Competent Cells, and Fetal Bovine Serum (all from Sigma Aldrich, Saint Louis, MO), and 
sodium phosphate monobasic monohydrate, sodium phosphate dibasic monohydrate, LB 
Broth Muller, Acrylamide/bis-acrylamide 40% solution, ammonium persulfate (APS), 
N,N,N',N'-Tetramethylethylenediamine (TEMED), 10x Tris Borate EDTA (TBE) (made in 
house - Tris HCl, Boric Acid, imidazole, and  sodium nitrate (all from Fisher Scientific, 
Fairlawn, NJ) were used as received. Additionally, an electrophoretic mobility shift assay 
(EMSA) kit (including EMSA dye, SYBR green, and SYPRO Ruby) (Life Technologies, 
now Thermofisher Scientific), ethylenediaminetetraacetic acid disodium salt dihydrate 
(EDTA), and silver nitrate (EMD Chemicals Inc., Gibbstown, NJ)), SOC Medium 
(Invitrogen, now Thermofisher Scientific), and human and bovine thrombin (Haematologic 
Technologies Inc., Essex Junction, VT) were used as received. A buffer solution of 140 mM 
3-(N-morpholino)propanesulfonic acid (MOPS) and 10 mM sodium nitrate was pHed to 7.6 
and filtered using Nalgene Rapid flow 0.2 µm nylon filters with 90 mm diameter 
(ThermoFisher Scientific, Waltham, MA) for experimentation. 
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2.4.2 Instrumentation 
Fluorescence measurements were performed on a Cary Eclipse Fluorimeter (Varian, 
Mulgrave, Australia), gels were run in a Bio-Rad box using a Bio-Rad volt (Hercules, CA). 
pH measurements were performed with a VWR Symphony SB70P meter (Radnor, PA). 
Gels were imaged using a Typhoon Trio from GE Healthcare (Piscataway, NJ) or a Biorad 
Gel Doc XR+ System (Hercules, CA). 
 
2.4.3 DNA sequences 
All sequences are written from the 5' to 3' end. 
Molecular Beacon Set: 
Molecular Beacon (Aptamer): [6FAM] TGA CTC TAC CAA TGT GAA CGT GAG TCA 
[Onyx Quencher A] 
MB Target (20 mer Activator): CTC AGT TCA CAT TGG TAG AG 
MB Competitor: TGA CTC TAC CAA TGT GAA CGT GAG TCA 
N Target (14 mer Activator w/ tail): CTC ACG TTC ACA TTT TAA CAG AT 
N Competitor: AAA TCT GTT AAA ATG TGA ACG TGA GTT 
 
Silver Ion Set: 
Silver 1 Aptamer (Ag1): AAC CAA TGC CTG GTT [Fluorescein dT]TT GCG ACC ACG 
CAA [Onyx Quencher A] 
Silver 1v2 Aptamer (Ag1v2): TAG TGT GCA ACG CTA GGA AGC GTT T[Fluorescein 
dT]T TTT TCC TAC CGT TGT AGG AAT G [Onyx Quencher A] 
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Silver 1v3 Aptamer (Ag1v3): GTA TAA TCG CGC TTA TA[Fluorescein dT] AAT TTG 
CCC GAA AAT TAG [Onyx Quencher A] 
Silver Competitor: CGG CCT GAC CGC GCC GTA TTT TTA CCC CGC CCT CAC CCC 
G  
Silver Full Activator:TTG CGT GGT CGC AAA AAC CAG GCA TTG GTT 
Silver Activator 10 mer (Act 10): TTG CGT GGT C 
Silver Activator 12 mer (Act 12): TTG CGT GGT CGC 
Silver Activator 14 mer (Act 14): TTG CGT GGT CGC AA 
Silver Activator 17 mer (Act 17): TTG CGT GGT CGC AAA AA 
Silver Activator 19 mer (Act 19): TTG CGT GGT CGC AAA AAC C 
Silver Activator 14 5’:ATT CCT ACA ACG GT 
Silver Activator 14 5’ A7G: ATT CCT GCA ACG GT 
Silver Activator 14 middle: GGT AGG AAA AAA AA 
Silver Activator 14 middle A8G: GGT AGG AGA AAA AA  
Silver 1v2 Stabilizer: CAT TCC TAC ACA CTA 
Silver 1v3 Stabilizer: CAT ATT TTT AAT C 
 
Thrombin Structure Switching Aptamer Set: 
TSSA1: [Fluoroscein dT]TA TAT TAA CCA GGT TGG TGT GGT TGG [Onyx Quencher 
A] 
TSSA2: TAT AT[Fluoroscein dT] AAC CAG GTT GGT GTG GTT GG[Onyx Quencher A] 
OG Ellington TSSA: [FAM] CCA ACG GTT GGT GTG GTT GG [BHQ-1] 
Competitor: TTT TTT TTT TTG GTT GGT GTG GTT GG 
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Activator 5: ATA TAT TTT T 
Activator 8: TTA ATA TAT T 
Activator 10: TGG TTA ATA T 
Activator 15: CAA CCT GGT TAA TAT 
Activator 20: CAC ACC AAC CTG GTT AAT AT 
Activator 25: CCA ACC ACA CCA ACC TGG TTA ATA T 
TAMRA TSSA1: [TAMRA] TAT ATT AAC CAG GTT GGT GTG GTT GG[BHQ-2] 
 
PfLDH Aptamer Set: 
PfLDH Aptamer: GTG TTT CTG GGC GGT AGA T(FAM)AC CAT AGT GAC CCA 
GCC TAT GG-BHQ-1 ATT TGT G 
PfLDH Competitor with T: TTC TGG GCG GTA GAT ACC ATA GTG ACC CAG AA 
PfLDH Competitor without T: TTC TGG GCG GTA GAA CCA TAG TGA CCC AGA A 
Stabilizer: CAC AAA TCC ATA GGA AAC AC 
 
Mercury (II) ion Set: 
Mercury Aptamer: TTC CAT GCG TGG AA[Fluorescein dT] TTG CGA CCT CGC AA 
[Onyx Quencher A] 
13 mer Activator: TTG CGA GGT CGC A 
17 mer Activator: TTG CGA GGT CGC AAA TT 
20 mer Activator: TTG CGA GGT CGC AAA TTC CA 
Competitor: CGC GAT TTC CCT TTC CCT TTC CCT TTC CCG TTT TTA CGG GTT 
TGG GTT TGG GTT TGG GTT TTC GCG 
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H-6 Set: 
3' Aptamer: CCT CAG ACA GGT TTG GTC TGG TTG G[BHQ-1]G TTT GGC TCC TGT 
GTA CGT [T-CAL Fluor Orange 560]CC AAA 
5' Aptamer: CC[T-CAL Fluor Orange 560] CAG ACA GGT TTG GTC TG[BHQ-1] GTT 
GGG TTT GGC TCC TGT GTA CGT TCC AAA 
Competitor: CGT ACA CAG GTT GGT CTG GTT GGG TTT GGC TCC TGT GTA CG 
Stabilizer/Activator: TTT GGA ACG TAC ATT CTG AGG 
 
2.4.4 Fluorescence Measurements 
Measurements for the molecular beacon, mercury, and PfLDH, aptamers with FAM 
dye were taken with excitation of 495 (± 5) nm and emission of 515 (± 10) nm with an 
average acquisition time of 0.5 s using a fluorescence cuvette from Starna Cells (Atascadero, 
CA). Measurements for the molecular beacon aptamer with TAMRA dye were taken with 
excitation of 550 (± 5) nm and emission of 580 (± 5) with an average acquisition time of 0.5 
s using the same quartz fluorescence cuvettes. Measurements for mercury (II) ions were 
performed in disposable fluorescence cuvettes from VWR (Radnor, PA). The MBA, 
mercury (II) ion, PfLDH, and H6 aptamer systems collected data using the Kinetics program 
from Varian with measurements taken every 0.2 min. Aptamers were used at 2 nM, with the 
activator and competitor added to the same tube at 2 uM.  
For the silver (I) ion and Thrombin Aptamer systems, scanning measurements were 
performed to determine any shift in the fluorescence emission peak. Excitation 
measurements of 495 (± 5) and an emission scan of 510 – 660 nm for FAM dye, or an 
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excitation of 560 (± 5) nm and emission scan of 575 – 660 (± 5) nm for TAMRA dye were 
utilized. Consistently across experiments measurements were performed with a scanning 
rate of 300 nm/min, an average acquisition time of 0.2 s and data acquisition every 1.0 nm.  
For the three-step calibration method for target determination experiments, either 
aptamer or target could be added to the blank solution as the first step. Followed by the 
addition of either target or aptamer (whichever had not previously been added). Upon 
equilibration, the competitor is then added, with another equilibration, and finally the 
activator is added and equilibrium established. For the molecular beacon, working 
concentrations of 2 nM for probe, 2 uM for competitor, and 2 uM for activator were used. 
Silver(I) probe used 10 nM of probe, 500 nM competitor, and 500 nM activator. Thrombin 
probe used 40 nM probe, 500 nM competitor, 500 nM activator.  
All measurements, for either the determination of the disassociation constant or 
target concentration, included a control of probe only with no target added. Experiments 
were performed using the temperature control at 20 °C. Control solutions always included 
an addition of the activator to ensure equal saturation before and after target addition.  
 
2.4.5 Data Analysis 
Data collected with the kinetics program. 
The last five data points were averaged for the reported data point. If there were 
multiple cuvettes for a data point the averages were performed for all of the last five data 
points. Therefore if there were two cuvettes, ten points would be averaged, five from one 
cuvette, and five from the other.  
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Data collected with the scan program. 
The background, or blank, scan was subtracted from all scans at a wavelength-by-
wavelength subtraction. The lambda max was determined with the target or activator scan, 
and this was used across all scans. At the lambda max, an average was performed of the max 
+/- 2 nm. This average was used as the data point. If there were multiple cuvettes for a data 
point, the averages were averaged, and the standard error was taken from the averages only. 
 
2.4.6 Gel Electrophoresis 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) gels were 
created by hand. The stacking portion of the gel was created using 3.07 mL diH2O, 1.25 mL 
1.0 M Tris HCl, 0.025 mL 0.5 % (w/v) SDS, 0.67 mL Acrylamide-bis (40:0.8), 0.025 mL 
Ammonium persulfate (APS), and 0.005 mL TEMED. The running portion was prepared 
using 10.2 mL diH2O, 7.5 mL 1.0 M Tris HCl, 0.15 mL 0.5 % (w/v) SDS, 12.0 mL 
Acrylamide-bis (40:0.8), 0.15 mL APS, and 0.02 mL TEMED. The running gel was first 
added to three-quarters of the gel mold, and water was added on the top to create a flat 
surface. After the gel polymerized, the water was poured off and the stacking portion was 
added to the top quarter, and the lane comb was added.  
Samples were prepared with sample buffer (10 % (w/v) SDS, 10 mM DTT, 20 % 
Glycerol (v/v), and 0.2 M Tris HCl), and heated to 95 °C for 10 minutes. After loading 
samples, gels were run at 180 V for 30 minutes with a running buffer of 25 mM Tris HCl, 
200 mM glycine, and 0.1 % (w/v) SDS. 
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2.4.7 Protein Transfection 
E. Coli BL21 (DE3) pLysS-T1R competent cells were transfected with plasmids for 
Plasmodium falciparium lactase dehydrogenase (PfLDH) and human lactase dehydrogenase 
(hLDHb) proteins using the protocol from Sigma-Aldrich. Briefly, cells, plasmids, and 
control DNA were removed from -80 °C storage and allowed to thaw on crushed ice for 5 
min. Control DNA was added to one tube of cells by adding 1 uL of cells and flicking the 
tube to mix then returned to ice. The PfLDH vector (at 29 ug/uL) was added to 2 tubes at 50 
ng/tube, and the hLDHb vector (at 9.5 ug/uL) was added to 2 tubes at 50 and 40 ng/tube 
respectively. Cells were incubated on ice for 30 minutes followed by heat shock at 37 °C in 
a water bath for 45 seconds and returned to ice for 2 minutes. Super Optimal broth with 
Catabolite reduction (SOC) medium was added to the cell tubes at 450 uL then the solutions 
were transferred to culture tubes and incubated at 42 °C with shaking at 230 rpm for an 
hour. Cell solutions were spread on kanamycin LB agar plates at 30, 60, and 90 uL per plate. 
Once dry, plates were incubated overnight in the warm room at 42 °C.  
Plates were determined to not have grown any cultures resulting from failed 
transfection. The liquid cultures were used again on plates, as the cultures were kept at 4 °C 
and parafilmed after use. Only hLDHb showed growth and three colonies were selected for 
growth overnight in liquid cultures. Cultures were split 1:50 for 100 mL growths and grown 
until OD600 = 0.5. Glycerol stocks were made for future use, while additional cultures were 
incubated overnight for vector miniprep. 
A StrataPrep Plasmid Miniprep kit (Stratagene) was used to retrieve plasmid DNA 
for sequencing; procedures were followed and described briefly here. Cultures were spun at 
15,000 rpm for 30 seconds to pellet and the supernatant was discarded. Multiple spindowns 
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were performed to get most of the supernatant off the sample. Cells were lysed using a 
stepwise addition of chemical 1,  and cells were re-suspended by vortexing, followed by 
additions of Chemical 2 and Chemical 3. Supernatant was removed after spinning for 5 
minutes and transferred to a microspin cup and spun for 30 seconds. Nuclease removal 
buffer was washed through the sample followed by wash buffer. The filtrate was kept and 
concentrations were found using the nanodrop; culture 1 was 89 ng/uL, culture 2 was 72.1 
ng/uL and culture 3 was 50 ng/uL. These samples were stored at -20 °C.  
The University of California Berkeley DNA Sequencing Facility sequenced samples. 
A total of 0.5 ug of cultures 1 and 2 were sent for processing. Culture 3 did not have a high 
enough concentration for sequencing. Results of the sequencing are shown in Figure 2.23. 
Additional tubes were left at -80 °C. 
 
2.4.8 Protein Purification 
Frozen stocks of clone 2 were pulled from the -80 °C freezer and 325 uL of the cells 
were added to 5 mL of LB with 35 mg/mL kanamycin. Tubes were incubated at 42 °C at 
201 rpm for 20 hours. Cells were split at 1:100 and grown for 3.5 hours to achieve an OD600 
of 0.51. IPDG was added at 0.5 mM to induce high protein production. Cells were incubated 
for an additional 4 hours then pelleted for 30 minutes at 5,000 rpm (2400 – 4400 x g), the 
supernatant was poured off and pellets were refridgerated overnight at 4 °C.  
 A lysis buffer (50 mM Tris HCl, 0.3 M NaCl, 20 mM imidazole, pH 7.5, SigmaFast 
Protein Inhibitor, >250 U benzonase) was added to the pellets, swirled, and let sit on ice for 
30 minutes. Pellets were re-dissolved using swirling and vortexing. Ultimately cells were 
lysed by sonication in a water bath. Lysed cells were transferred to centrifuge tubes for 
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pelleting at 14,000 rpm for 20 minutes. Pellets were kept as a control, and supernatant was 
loaded onto a GE Healthcare His-trap crude column (1 mL). After loading the supernatant, it 
was allowed to interact with the column for 1.5 hours before performing a wash (HK Buffer: 
25 mM Tris HCl, 0.1 M NaCl, 20 mM Imidazole, pH 7.5) of 40 mL and letting sit for an 
additional hour.  
The column was eluded with 5 column equivalents (5 mL) each of increasing 
concentrations of imidazole in HK buffer. The four concentrations were 50, 100, 250, and 
500 mM imidazole total in HK buffer (instead of 20 mM). Each of these increasing 
concentrations were considered a fraction, with the last imidazole concentration split into 5 
fractions of 1 mL each. Each fraction was measured using UV/Vis spectroscopy at 
wavelengths of 260, 280, and 320 nm. Protein concentration was determined using the 
equation: 
 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 = 1.55 𝜆!"# − 0.76(𝜆!"#) Eqn. 3 
 
Samples with concentrations above 0.2 were considered to have the protein hLDHb in high 
and pure enough concentrations. 
 SDS-PAGE gel was performed on the fractions to confirm the contents of the 
fractions. As compared to provided PfLDH, approximately the same MW as hLDHb, 
fractions 4-11 have the same MW, but have two bands, one in a distinctly higher molecular 
weight band than the expected LDH band.  
Fractions 6 – 11 were pooled (~10 mL) and concentrated using a 3 KDa MW cutoff 
spin method for 20 minutes at 2400 x g. Fractions 4 and 5 were not included as they did not 
contain any protein according to the spectroscopy analysis. After this concentration, the 
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concentrated portion was transferred to another concentrator with 30,000 Da cutoff and spun 
for 20 minutes at 2400 x g 4x to obtain ~ 1 mL of concentrated protein. This protein was 
stored at -20 °C and used in experiments with his-tags and for PfLDH experiments.  
The concentrated protein was then dialyzed using a Thermo-fisher slyde-a-lyzer 
dialysis cassette with a 3500 MW cutoff for volumes of 0.5 – 3.0 mL to remove excess 
imidazole. Dialysis was performed with HK buffer for 3 hours, and then buffer was 
exchanged for fresh, and left for 48 hours.  
 
Figure 2.23 Sequence alignment of human LDH b with two different transfection colony clones. The 
asterisks under the alignment show an exact match. 
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This chapter in part adapted from: 
Kallewaard-Lum, H.M., Larisch, M., and Plaxco, K.W. 2016. “A single-tube, three-
measurement approach to calibrated beacons using DNA structure switching aptamers in 
complex samples.” In Preparation. 
 
  59 
Chapter 3. References 
 
1 Scott, J.D., and Gretch, D.R. 2007. “Molecular diagnostics of hepatitis C virus infection: a 
systematic review.” Journal of the American Medical Association, 297, 724-732. 
2 Tang, Y.W., Procop, G.W., and Persing, D.H. 1997. “Molecular diagnostics of infectious 
diseases.” Clinical Chemistry, 43, 2021-2038. 
3 Brennan, D.J., O’Connor, D.P., Rexhepaj, E., Ponten, F., and Gallagher, W.M. 2010. 
“Antibody-based proteomics: fast-tracking molecular diagnostics in oncology.” 
Nature Reviews Cancer, 10, 605-617. 
4 Evans, W.E., and Relling M.V. 1999. “Pharmacogenomics: Translating Functional 
Genomics into Rational Therapeutics.” Science, 286, 487-491. 
5 Barany, F. 1991. “Genetic disease detection and DNA amplification using cloned 
thermostable ligase.” Proceeding of the National Academy of the United States of 
America, 88, 189-193. 
6 Bennett, P.R., Le Van Kim, C., Colin, Y., Warwick, R.M., Chérif-Zahar, B., Fisk, N.M., 
and Cartron, J.P. 1993. “Prenatal determination of fetal RhD type by DNA 
Amplification.” New England Journal of Medicine, 329, 607-610. 
7 Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., Guo, J., Zhang, Y., Chen, J., Guo, 
X., Li, Q., Li, X., Wang, W., Zhang, Y., Wang, J., Jiang, X., Xiang, Y., Xu, C., 
Zheng, P., Zhang, J., Li, R., Zhang, H., Shang, X., Gong, T., Ning, G., Wang, J., 
Zen, K., Zhang, J., and Zhang, C.Y. 2008. “Characterization of microRNAs in 
serum: a novel class of biomarkers for diagnosis of cancer and other diseases.” Cell 
Research, 18, 997-1006. 
  60 
 
8 Petricoin, E.F., Belluco, C., Araujo, R.P., Liotta, L.A. 2006. “The blood peptidome: a 
higher dimension of information content for cancer biomarker discovery.” Nature 
Reviews Cancer, 6, 961-967. 
9 Eisenstein, B.I. 1990. “The Polymerase Chain Reaction – A New Method of Using 
Molecular Genetics for Medical Diagnosis.” New England Journal of Medicine, 322, 
178-183. 
10 Klein, D. 2002. “Quantification using real-time PCR technology: applications and 
limitations.” Trends in Molecular Medicine, 8, 257-260. 
11 Manor, P.G. 1999. “Turnaround times in the laboratory: a review of the literature.” 
Clincal Laboratory Science, 12, 85-89. 
12 Hawkins, R.C. 2007. “Laboratory Turnaround Time.” Clinical Biochemistry Reviews, 28, 
179-194. 
13 Gage, J.C., Ferreccio, C., Gonzales, M., Arroyo, R., Huivín, M., and Robles, S.C. 2003. 
“Follow-up care of women with an abnormal cytology in a low-resource setting.” 
Cancer Detection and Prevention, 27, 466-471. 
14 Yager, P., Domingo, G.J., and Gerdes, J. 2008. “Point-of-Care Diagnostics for Global 
Health.” Annual Review of Biomedical Engineering, 10, 107-144. 
15 Wide, L., and Gemzell, C.A. 1960. “An Immunological Pregnancy Test.” Acta 
Endocrinology, 35, 261-267. 
16 Williams, D.L., Doig Jr., A.R., and Korosi, A. 1970. “Electrochemical-enzymatic analysis 
of blood glucose and lactate.” Analytical Chemistry, 41, 118-121. 
17 Heller, M.J. 2002. “DNA Microarray Technology: Devices, Systems, and Applications.” 
Annual Review of Biomedical Engineering, 4, 129-153. 
  61 
 
18 Chang, T-W. 1983. “Binding of cells to matrixes of distinct antibodies coated on solid 
surface.” Journal of Immunological Methods, 65, 217-223. 
19 Chinnasamy, T.; Segerink, L.I.; Nystrand, M.; Gantelius, J.; Svahn, H.A. A lateral flow 
paper microarray for rapid allergy point of care diagnostics. Analyst 2014, 139, 
2348-2354.  
20 Buchegger, P.; Sauer, U.; Toth-Székély, H.; and Preininger, C. Miniaturized Protein 
Microarray with Internal Calibration as Point-of-Care Device for Diagnosis of 
Neonatal Sepsis. Sensors 2012, 12, 1494-1508.  
21 Hansen, R.R.; Johnson, L.M.; and Bowman, C.N. Visual, base-specific detection of 
nucleic acid hybridization using polymerization-based amplification. Anal. 
Biochemistry 2009, 386, 285-287.  
22 Walker, F.M., Ahmad, K.M., Eisenstein, M., and Soh, H.T. 2014. “Transformation of 
Personal Computers and Mobile Phones into Genetic Diagnostic Systems.” 
Analytical Chemistry, 86, 9236-9241. 
23 Engvall, E., and Perlmann, P. 1971. “Enzyme-linked immunosorbent assay (ELISA) 
quantitative assay of immunoglobulin G.” Immunochemistry, 8, 871-874. 
24 Tuerk, C., and Gold, L. 1990. “Systematic evolution of ligands by exponential 
enrichment: RNA ligands to bacteriophage T4 DNA-polymerase.” Science, 249, 
505-510. 
25 Ellington, A.D., and Szostak, J.W. 1990. “In vitro selection of RNA molecules that bind 
specific ligands.” Nature, 346, 818-822. 
26 Robertson, D.L., and Joyce, G.F. 1990. “Selection in vitro of an RNA enzyme that 
specifically cleaves single-stranded DNA”. Nature, 344, 467-468. 
  62 
 
27 Stone, S.R., and Tapparelli, C. 1994. “Thrombin Inhibitors and Antithrombotic Agents: 
The Importance of Rapid Inhibition.” Journal of Enzyme Inhibition, 9, 3-15. 
28 Stojanovic, M.N., de Prada, P., and Landry, D.W. 2001. “Aptamer-Based Folding 
Fluorescent Sensor for Cocaine.” Journal of the American Chemical Society, 123, 
4928-4931. 
29 Tombelli, S., Minunni, M., and Mascini, M. 2007. “Analytical applications of aptamers.” 
Proceedings of SPIE: International Society of Optical Engineering, 6565, 65850W. 
30 Cho, E.J., Lee, J.W., and Ellington, A.D. 2009. “Applications of Aptamers as Sensors.” 
Annual Review of Analytical Chemistry, 2, 241-264. 
31 Deng, B., Lin, Y., Wang, C., Li, F., Wang, Z., Zhang, H., Li, X.F., and Le, X.C. 2014. 
“Aptamer binding assays for proteins: The thrombin example – A review.” Analytica 
Chimica Acta, 837, 1-15. 
32 Griffin, L.C., Toole, J.J., and Leung, L.L.K.  1993. “The discovery and characterization of 
a novel nucleotide-based thrombin inhibitor.” Gene, 137, 25-31. 
33 Burge, S. Parkingson, G.N., Hazel, P., Todd, A.K., and Neidle, S. 2006. “Quadruplex 
DNA: Sequence, topology and structure.” Nucleic Acids Research, 34, 5402-5415. 
34 Bochman, M.L., Paeschke, K., and Zakian, V.A. 2012. “DNA secondary structures: 
stability and function of G-quadruplex structures.” Nature Reviews Genetics, 13, 
770-780. 
35 Tasset, D.M., Kubik, M.F., and Steiner, W. 1997. “Oligonucleotide Inhibitors of Human 
Thrombin that Bind Distinct Epitopes.” Journal of Molecular Biology, 272, 688-698. 
  63 
 
36 Cho, M., Oh, S.S., Nie, J., Stewart, R., Radeke, M.J., Eisentein, M., Coffey, P.J., 
Thomson, J.A., and Soh, H.T. 2015. “Array-based Discovery of Aptamer Pairs.” 
Analytical Chemistry, 87, 821-828. 
37 Ahmad, K.M., Xiao, Y., and Soh, H.T. 2012. “Selection is more intelligent than design: 
imporving the affinity of a bivalent ligand through directed evolution.” Nucleic Acids 
Research, 40, 11777-11783. 
38 Song, S., Wang, L., Li, J., Fan, C., and Zhao, J. 2008. “Aptamer-based biosensors.” 
Trends in Analytical Chemistry, 27, 108-117.  
39 Bunka, D.H.J., and Stockley, P.G. 2006. “Aptamers come of age – at last.” Nature 
Reviews Microbiology, 4, 588-596. 
40 Lauhon, C.T., and Szostak, J.W. 1995. “RNA aptamers that bind flavin and nicotinamide 
redox cofactors.” Journal of the American Chemical Society, 117, 1246-1257. 
41 Travascio, P., Bennet, A.J., Wang, D.J., and Sen, D. 1999. “A ribozyme and catalytic 
DNA with peroxidase activity: active site versus cofactor-binding sites.” Chemical 
Biology, 6, 779-787. 
42 Walsh, R., and DeRosa, M.C. 2009. “Retention of function in the DNA homolog of the 
RNA dopamine aptamer.” Biochemical and Biophysical Research Communications, 
388, 732-735. 
43 Thiel, K.W., and Giangrande, P.H. 2009. “Therapeutic Applications of DNA and RNA 
Aptamers.” Oligonucleotides, 19, 209-222. 
44 Gold, L., Walker, J.J., Wilcox, S.K., and Williams, S. 2012. “Advances in human 
proteomics at high scale with the SOMAscan proteomics platform.” Nature 
Biotechnology, 29, 543-539. 
  64 
 
45 Liu, J., Lee, J.H., and Lu, Y. 2007. “Quantum Dot Encoding of Aptamer-Linked 
Nanostructures for One-Pot Simultaneous Detection of Multiple Analytes.” 
Analytical Chemistry, 79, 4120-4125. 
46 Johannsen, B., Noll, B., Leibnitz, P., Reck, G., Noll, S., and Spies, H. 1993. “Technetium 
and rhenium complexes of mercapto-containing peptides 1. Tc(V) and Re(V) 
complexes with mercaptoacetyl diglycine (MAG2) and X-ray structure of 
AsPh4[TcO(MAG2)]C2H5OH.” Inorganica Chimica Acta, 210, 209-214. 
47 Da Pieve, C., Perkins, A.C., and Missailidis, S. 2009. “Anti-MUC1 aptamers: 
radiolabelling with 99mTc and biodistribution in MCF-7 tumour-bearing mice.” 
Nuclear Medicine and Biology, 36, 703-710. 
48 Bock, L.C., Griffin, L.C., Latham, J.A., Vermaas, E.H., and Toole, J.J. 1992. “Selection 
of single-stranded DNA molecules that bind and inhibit human thrombin.” Nature, 
355, 564. 
49 Jiang, Y., Fang, X., and Bai, C. 2004. “Signaling Aptamer/Protein Binding by a Molecular 
Light Switch Complex.” Analytical Chemistry, 76, 5230-5235. 
50 Fang, X., Cao, Z., Beck, T., and Tan, W. 2001. “Molecular Aptamer for Real-Time 
Oncoprotein Platelet-Derived Growth Factor Monitoring by Fluorescence 
Anisotropy.” Analytical Chemistry, 73, 5753-5757. 
51 Stojanovic, M.N., de Prada, P., and Landry, D.W. 2000. “Fluorescent Sensors Based on 
Aptamer Self-Assembly.” Journal of the American Chemical Society, 122, 11547-
11548. 
52 Nutiu, R., and Li, Y. 2003. “Structure-Switching Signaling Aptamers.” Journal of the 
American Chemical Society, 125, 4771-4778. 
  65 
 
53 Nutiu, R., and Li, Y. 2005. “In Vitro Selection of Structure-Switching Signaling 
Aptamers.” Angewandte Chemie, 117, 1085-1089. 
54 Protein Data Bank. http://www.pdb.org (accessed April 12, 2016). 
55 Nutiu, R., and Li, Y. 2004. “Structure-Switching Signaling Aptamers: Transducing 
Molecular Recognition into Fluorescence Signaling.” Chemistry A European 
Journal, 10, 1868-1876. 
56 Chen, J., Fang, Z, Liu, J., and Zeng, L. 2012. “A simple and rapid biosensor for 
ochratoxin A based on a structure-switching signaling aptamer.” Food Control, 25, 
555-560.  
57 Lau, P.S., Lai, C.K., and Li, Y. 2013. “Quality Control Certification of RNA Aptamer-
Based Detection.” ChemBioChem, 14, 987-992. 
58 Xia, Y., Gao, P., Qiu, X., Gan, S., Yang, H., and Huang, S. 2012. “Aptasensor based on 
triplex switch for SERS detection of cytochrome c.” Analyst, 137, 5705-5709. 
59 Cunningham, J.C., Brenes, N.J., and Crooks, R.M. 2014. “Paper Electrochemical Device 
for Detection of DNA and Thrombin by Target-Induced Conformational Switching.” 
Analytical Chemistry, 86, 6166-6170. 
60 Sun, L., Frykholm, K., Fornander, L.H., Svedhem, S., Weserlund, F., and Åkerman, B. 
2014. “Sensing Conformational Changes in DNA upon Ligand Binding Using QCM-
D. Polyamine Condensation and Rad51 Extension of DNA layers.” Journal of 
Physical Chemistry B, 118, 11895-11904. 
61 Sorgenfrei, S., Chiu, C., Gonzalez Jr., R.L., Yu, Y-J., Kim, P., Nuckolls, C., and Shepard, 
K.L. 2011. “Label-free single-molecule detection of DNA-hybridization kinetics 
with a carbon nanotube field-effect transistor.” Nature Nanotechnology, 6, 126-132. 
  66 
 
62 Tavares, A.J., Noor, M.O., Uddayasankar, U., Krull, U.J., and Vannoy, C.H. 2014. “Solid-
Phase Supports for the in situ Assembly of Quantum Dot-FRET Hybridization 
Assays in Channel Microfluidics.” Methods in Molecular Biology, 1199, 241-255. 
63 Liu, X., Freeman, R., Golub, E., and Willner, I. 2011. “Chemiluminescence and 
Chemiluminescence Resonance Energy Transfer (CRET) Aptamer Sensors Using 
Catalytic Hemin/G-Quadruplexes.” ACS Nano, 5, 7648-7655. 
64 Zhao, T., Liu, R., Ding, X., Zhao, J., Yu, H., Wang, L., Xu, Q., Wang, X., Lou, X., He, 
M., and Xiao, Y.  2015. “Nanoprobe-Enhanced, Split Aptamer-Based 
Electrochemical Sandwich Assay for Ultrasensitive Detection of Small Molecules.” 
Analytical Chemistry, 87, 7712-7719.  
65 Alsager, O.A., Kumar, S., Zhu, B., Travas-Sejdic, J., McNatty, K.P., and Hodgkiss, J.M. 
2015. “Ultrasensitive Colorimetric Detection of 17β-Estradiol: The Effect of 
Shortening DNA Aptamer Sequences.” Analytical Chemistry, 87, 4201 – 4209. 
66 Bonham, A.J., Hsieh, K., Ferguson, B.S., Vallée-Bélisle, A., Ricci, F., Soh, H.T., and 
Plaxco, K.W. 2012. “Quantification of Transcription Factor Binding in Cell Extracts 
Using an Electrochemical, Structure-Switching Biosensor.” Journal of the American 
Chemical Society, 134, 3346-3348. 
67 Zhuang, J., He, Y., Chen, G., and Tang, D. 2014. “Binding-induced internal-displacement 
of inverted aptamer beacon: Toward a novel electrochemical detection platform.” 
Electrochemistry Communications, 47, 25-28. 
68 Vallée-Bélisle, A., Bonham, A.J., Reich, N.O., Ricci, F., and Plaxco, K.W. 2011. 
“Transcription Factor Beacons for the Quantitative Detection of DNA Binding 
Activity.” Journal of the American Chemical Society, 133, 13836-13839. 
  67 
 
69 Tyagi, S., and Kramer, F.R. 1995. “Molecular Beacons: Probes that Fluoresce upon 
Hybridization.” Nature Biotechnology, 14, 303-308. 
70 Guo, J., Ju, J., and Turro, N.J. 2012. “Fluorescent hybridization probes for nucleic acid 
detection.” Analytical and Bioanalytical Chemistry, 402, 3115-3125. 
71 Watzinger, F., Ebner, K., and Lion, T. 2006. “Detection and monitoring of virus infections 
by real-time PCR.” Molecular Aspects of Medicine, 27, 254-298. 
72 Fang, X., Mi, Y., Li, J.J., Beck, T., Schuster, S., and Tan, W. 2002. “Molecular beacons: 
Fluorogenic probes for living cell study.” Cell Biochemistry and Biophysics, 37, 71-
81. 
73 Hamaguchi, N., Ellington, A., and Stanton, M. 2001. “Aptamer Beacons for the direct 
detection of proteins.” Analytical Biochemistry, 294, 126-131. 
74 Liu, J., Cao, Z., and Lu, Y. 2009. “Functional Nucleic Acid Sensors.” Chemical Reviews, 
109, 1948-1998. 
75 Nutiu, R., and Li, Y. 2003. “Structure-Switching Signaling Aptamers.” Journal of the 
American Chemical Society, 125, 4771-4778. 
76 Zheng, D., Zou, R., and Lou, X. 2012. “Label-Free Fluorescent Detection of Ions, 
Proteins, and Small Molecules Using Structure-Switching Aptamers, SYBR Gold, 
and Exonuclease I.” Analytical Chemistry, 84, 3554-3560. 
77 Tanaka, K., Yamada, Y., and Shinoya, M. 2002. “Formation of Silver(I)-Mediated DNA 
Duplex and Triplex through an Alternative Base Pair of Pyridine Nucleobases.” 
Journal of the American Chemistry Society, 124, 8802-8803. 
  68 
 
78 Porchetta, A., Vallée-Bélisle, A., Plaxco, K.W., and Ricci, R. 2013. “Allosterically 
Tunable, DNA-Based Switches Triggered by Heavy Metals.” Journal of the 
American Chemical Society, 135, 13238-13241. 
79 Clever, G.H., Kaul, C., and Carell, T. 2007. “DNA-Metal Base Pairs.” Angewandte 
Chemie International Edition, 46, 6226-6236.  
80 Bury, N.R., McGeer, J.C., and Wood, C.M. 1999. “Effects of altering freshwater 
chemistry on physiological responses of rainbow trout to silver exposure.” 
Environmental Toxicology and Chemistry, 18, 49-55. 
81 Bianchini, A., Grosell, M., Gregory, S.M., and Wood, C.M. 2002. “Acute Silver Toxicity 
in Aquatic Animals Is a Function of Sodium Uptake Rate.” Environmental Science 
and Technology, 36, 1763-1766. 
82 Cheung, Y.W., Kwok, J., Law, A.W.L., Watt, R.M., Kotaka, M., and Tanner, J.A. 2013. 
“Structural basis for discriminatory recognition of Plasmodium lactate 
dehydrogenase by a DNA aptamer.” Proceedings of the National Academy of 
Sciences of the United States of America, 110, 15967-15972. 
83 Tan, X., Chen, W., Lu, S., Zhu, Z., Chen, T., Zhu, G., You, M., and Tan, W. 2012. 
“Molecular Beacon Aptamers for Direct and Universal Quantitation of Recombinant 
Proteins from Cell Lysates.” Analytical Chemistry, 84, 8272-8276. 
84 Doyle, M.B., Murphy, S. A. 2005. “Aptamers and methods for their in vitro selection and 
uses thereof.” US Patent Application Publication, US20050142582 A1, June 30, 
2005.  
  69 
 
85 Li, L., Li, B., Qi, Y., and Jin, Y. 2009. “Label-free aptamer-based colorimetric detection 
of mercury ions in aqeous media using unmodified gold nanoparticles as colorimetric 
probe.” Analytical and bioanalytical Chemistry, 393, 2051-2057. 
86 Xia, F., Zuo, X., Yang, R., Xiao, Y., Kang, D., Vallée-Bélisle, A., Gong, X., Yuen, J.D., 
Hsu, B.B.Y., Heeger, A.J., and Plaxco, K.W. 2010. “Colorimetric detection of DNA, 
small molecules, proteins, and ions using unmodified gold nanoparticles and 
conjugated polyelectrolytes.” Proceedings of the National Academy of Sciences of 
the United States of America, 107, 10837-1041. 
87 Porchetta, A., Vallée-Bélisle, A., Plaxco, K.W., and Ricci, F. 2013. “Allosterically 
tunable, DNA-based switches triggered by heavy metals.” Journal of the American 
Chemical Society, 135, 13238-13241. 
